You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 21, 2025

Details for Patent: 11,266,635


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,266,635 protect, and when does it expire?

Patent 11,266,635 protects QINLOCK and is included in one NDA.

This patent has twenty-two patent family members in twelve countries.

Summary for Patent: 11,266,635
Title:Methods of treating gastrointestinal stromal tumors
Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Inventor(s): Soto; Rodrigo Ruiz (Waltham, MA), Rosen; Oliver (Waltham, MA), Pitman; Jama (Waltham, MA)
Assignee: Deciphera Pharmaceuticals, LLC (Waltham, MA)
Application Number:17/180,218
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 11,266,635: A Comprehensive Analysis

Introduction

Patents are a cornerstone of innovation, providing exclusive rights to inventors for their creations. The United States Patent and Trademark Office (USPTO) is responsible for granting these patents, ensuring they meet strict criteria of novelty, nonobviousness, and utility. This article delves into the specifics of United States Patent 11,266,635, examining its scope, claims, and the broader patent landscape.

Patent Basics

Before diving into the specifics of Patent 11,266,635, it is essential to understand the basic structure of U.S. patent law. Patents must be useful, novel, and nonobvious, and they must claim patentable subject matter[4].

Patent 11,266,635 Overview

Inventorship and Assignment

To begin, it is crucial to identify the inventors and assignees of the patent. Correct inventorship is a critical aspect of patent law, as errors can lead to the patent being unenforceable[5].

Patent Claims

The claims section of a patent is its most critical part, as it defines the scope of the invention. Claims must be clear, concise, and supported by the patent's specification. For Patent 11,266,635, each claim would need to be analyzed to understand what is being protected.

Claim Types

Independent Claims

Independent claims stand alone and define the invention without reference to other claims. These claims are crucial as they set the broadest scope of the invention.

Dependent Claims

Dependent claims refer back to one or more previous claims and narrow the scope of the invention. They often add specific details or limitations to the independent claims.

Patent Scope and Coverage

The scope of a patent is determined by its claims. For Patent 11,266,635, the scope would include all variations of the invention that fall within the language of the claims. This includes any equivalents that might be considered under the doctrine of equivalents.

Prior Art and Novelty

To be patentable, an invention must be novel, meaning it must not be fully anticipated by prior art. The USPTO examiner would have reviewed existing patents, publications, and other state of the art knowledge to ensure that Patent 11,266,635 meets this criterion[4].

Nonobviousness

In addition to novelty, the invention must also be nonobvious. This means that the invention must not have been readily within the ordinary skills of a competent artisan at the time it was made. The examiner would have considered whether the differences between the invention and the prior art would have been obvious to one skilled in the field[4].

Utility

The invention must also be useful, providing some tangible benefit. This requirement ensures that the patent is for a functional and operable invention[4].

Patent Term and Adjustments

Patents have a limited term, typically 20 years from the filing date of the earliest non-provisional application. However, this term can be adjusted due to delays during the prosecution process. For example, Patent Term Adjustments (PTA) can extend the term if there are delays caused by the USPTO[1].

Obviousness-Type Double Patenting (ODP)

ODP is a doctrine that prevents an inventor from securing a second, later-expiring patent for an invention that is not patentably distinct from a first patent. This is particularly relevant in cases where multiple patents are derived from the same application or family of applications[1].

Terminal Disclaimers

In cases where ODP is an issue, inventors may file terminal disclaimers to overcome the rejection. This involves disclaiming the term of the later patent beyond the expiration date of the earlier patent. However, this does not extend the term of the patent past the specified date[1].

Economic and Research Implications

Patents like 11,266,635 contribute to the broader economic landscape by encouraging innovation and investment. The USPTO's Patent Claims Research Dataset provides insights into patent scope and claims, helping researchers and policymakers understand the impact of patents on innovation[3].

Industry Expert Insights

Industry experts often emphasize the importance of clear and well-defined claims. As noted by Alan C. Marco and Joshua D. Sarnoff in their work on patent claims and scope, "the clarity and precision of patent claims are critical to ensuring that patents serve their intended purpose of promoting innovation"[3].

Illustrative Statistics

The USPTO grants thousands of patents annually, each contributing to the complex patent landscape. For instance, between 1976 and 2014, the USPTO granted over 5 million patents, with each patent having an average of around 20 claims[3].

Real-World Applications

Understanding the scope and claims of a patent like 11,266,635 is crucial for companies looking to innovate or avoid infringement. For example, a company developing a new product would need to ensure that their product does not infringe on the claims of existing patents.

Challenges and Controversies

Patent law is not without its challenges. Issues such as patent trolls, overly broad claims, and disputes over inventorship can complicate the landscape. The case of In re Cellect LLC highlights the complexities surrounding ODP and terminal disclaimers[1].

Future Trends

As technology advances, the patent landscape continues to evolve. Emerging fields like AI, biotechnology, and renewable energy are driving new patent applications and challenges. The USPTO and courts must adapt to these changes to ensure that the patent system continues to promote innovation.

Key Takeaways

  • Clear Claims: The claims section of a patent is crucial and must be clear and well-defined.
  • Novelty and Nonobviousness: Patents must meet strict criteria of novelty and nonobviousness.
  • Utility: The invention must provide a tangible benefit.
  • Patent Term Adjustments: Delays during prosecution can lead to adjustments in the patent term.
  • ODP and Terminal Disclaimers: These are important considerations in managing patent families.

Frequently Asked Questions

What is the significance of the claims section in a patent?

The claims section defines the scope of the invention and is the most critical part of the patent.

How is the novelty of an invention determined?

Novelty is determined by comparing the invention to prior art, ensuring it is not fully anticipated by existing patents, publications, or other state of the art knowledge.

What is obviousness-type double patenting (ODP)?

ODP prevents an inventor from securing a second, later-expiring patent for an invention that is not patentably distinct from a first patent.

How do terminal disclaimers work in patent law?

Terminal disclaimers involve disclaiming the term of a later patent beyond the expiration date of an earlier patent to overcome ODP rejections.

Why is correct inventorship important in patent law?

Correct inventorship is crucial because errors can lead to the patent being unenforceable, and deceptive intent in naming inventors can invalidate the patent entirely.

Cited Sources:

  1. In re Cellect LLC, United States Court of Appeals for the Federal Circuit, August 28, 2023.
  2. U.S. Patent and Trademark Office (USPTO), USAGov.
  3. Patent Claims Research Dataset, USPTO.
  4. Patents and Innovation Policy, CRS Reports, August 2, 2022.
  5. Determining Inventorship for US Patent Applications, Oregon State University.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 11,266,635

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Deciphera Pharms QINLOCK ripretinib TABLET;ORAL 213973-001 May 15, 2020 RX Yes Yes 11,266,635 ⤷  Try for Free TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM PALMER-PLANTER ERYTHRODYSESTHESIA SYNDROME ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,266,635

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 122301 ⤷  Try for Free
Australia 2020328538 ⤷  Try for Free
Australia 2020329956 ⤷  Try for Free
Australia 2023286024 ⤷  Try for Free
Australia 2024259651 ⤷  Try for Free
Brazil 112022002609 ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.